A phase 3 trial shows no impact of the anticoagulant rivaroxaban on the risk of cognitive decline in individuals with atrial fibrillation and low thromboembolic risk — highlighting the need for a better understanding of the mechanisms that link these conditions.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Rivard, L. et al. Circulation 145, 392–409 (2022).
Rivard, L. et al. Nat. Med. https://doi.org/10.1038/s41591-025-04101-y (2025).
Rahman, A. A. et al. Neurology 100, e1309–e1320 (2023).
Mobley, A. R. et al. Nat. Med. 30, 2288–2294 (2024).
Kim, D. et al. Eur. Heart J. 40, 2313–2323 (2019).
de Bruijn, R. F. et al. JAMA Neurol. 72, 1288–1294 (2015).
Patel, R. et al. Brain Commun. 7, fcaf222 (2025).
Chung, S. C. et al. JACC Adv. 2, 100655 (2023).
Kopecek, M., Bezdicek, O., Sulc, Z., Lukavsky, J. & Stepankova, H. Int. J. Geriatr. Psychiatry 32, 868–875 (2017).
Van Gelder, I. C. et al. Eur. Heart J. 45, 3314–3414 (2024).
Romiti, G. F. et al. Thromb. Haemost. 122, 406–414 (2022).
Yang, P. S. et al. J. Clin. Med. 9, 1696 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.P. declares speaker activity for Pfizer and BMS/JJ Alliance and consulting activity for Regeneron Pharmaceuticals; M.P. is also the Italian national principal investigator of the AFFIRMO project on multimorbidity in atrial fibrillation, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant 899871. G.F.R. declares consultancy for Boehringer Ingelheim and an educational grant from Anthos, outside of this work. No fees are directly received personally.
Rights and permissions
About this article
Cite this article
Proietti, M., Romiti, G.F. Understanding the link between atrial fibrillation and cognitive decline. Nat Med 32, 40–41 (2026). https://doi.org/10.1038/s41591-025-04127-2
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-025-04127-2
